Literature DB >> 11756990

Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine.

Colin M Gelder1, Rob Lambkin, Keith W Hart, Douglas Fleming, O Martin Williams, Mike Bunce, Kenneth I Welsh, Sara E Marshall, John Oxford.   

Abstract

Influenza remains a major cause of morbidity and mortality, particularly in at-risk groups where vaccination reduces complications of infection but is not universally protective. In order to determine whether human leukocyte antigen (HLA) class II polymorphisms modulate anti-influenza antibody responses to vaccination, a cohort of HLA-typed at-risk donors was investigated. The subjects were recruited from a single urban family practice. Hemagglutination-inhibition (HAI) titers were measured immediately before and 28 days after subunit vaccination. Nonresponsiveness was defined as failure to mount an HAI response to any component of the trivalent influenza vaccine. When the nonresponders and responders with HLA class II were compared, the nonresponder group had more HLA-DRB1*07-positive donors (13/32 vs. 6/41 responders; P=.016, Fisher's exact test) and fewer HLA-DQB1*0603-9/14-positive donors (2/32 vs. 14/41 responders; P=.0045). Thus, polymorphisms in HLA class II molecules appear to modulate antibody responses to influenza vaccination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11756990     DOI: 10.1086/338014

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Comparison of complement fixation and hemagglutination inhibition assays for detecting antibody responses following influenza virus vaccination.

Authors:  Harry E Prince; Amy L Leber
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

2.  Genetic determinants of immune-response to a polysaccharide vaccine for typhoid.

Authors:  Partha P Majumder; Herman F Staats; Neeta Sarkar-Roy; Binuja Varma; Trina Ghosh; Sujit Maiti; K Narayanasamy; Carol C Whisnant; James L Stephenson; Diane K Wagener
Journal:  Hugo J       Date:  2010-03-11

Review 3.  Impact of host genetic polymorphisms on vaccine induced antibody response.

Authors:  Janina E Linnik; Adrian Egli
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

4.  Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting.

Authors:  Kathryn Edwards; Germaine Hanquet; Steve Black; Emmanuel Mignot; Christopher Jankosky; Tom Shimabukuro; Elizabeth Miller; Hanna Nohynek; Pieter Neels
Journal:  Biologicals       Date:  2019-05-23       Impact factor: 1.856

5.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

Review 6.  Vaccinomics: current findings, challenges and novel approaches for vaccine development.

Authors:  Inna G Ovsyannikova; Gregory A Poland
Journal:  AAPS J       Date:  2011-06-14       Impact factor: 4.009

Review 7.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

Review 8.  Factors affecting immune responses to the influenza vaccine.

Authors:  Maria R Castrucci
Journal:  Hum Vaccin Immunother       Date:  2017-07-21       Impact factor: 3.452

Review 9.  Immunogenetics of seasonal influenza vaccine response.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

10.  Genomic correlates of variability in immune response to an oral cholera vaccine.

Authors:  Partha P Majumder; Neeta Sarkar-Roy; Herman Staats; T Ramamurthy; Sujit Maiti; Goutam Chowdhury; Carol C Whisnant; K Narayanasamy; Diane K Wagener
Journal:  Eur J Hum Genet       Date:  2012-12-19       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.